# RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

> **NCT03215095** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Durvalumab (Medi4736)
- **RADIATION:** Radioiodine (RAI)

## Key facts

- **NCT ID:** NCT03215095
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-10
- **Primary completion:** 2023-02-06
- **Final completion:** 2026-07
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-07-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03215095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03215095, "RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03215095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*